Glomerular diseases: emerging tests and therapies for IgA nephropathy.
The last decade has seen major progress in understanding the pathogenesis as well as the prognosis and treatment of patients with IgA nephropathy (IgAN). Although the diagnostic criterion of a kidney biopsy demonstrating dominant or codominant IgA deposition remains unchanged, much more is known about the genetic and environmental factors predisposing to disease development and progression. These advances have led to the identification of novel diagnostic and prognostic markers. Among the most promising clinically are genetic profiling, quantification of galactose-deficient IgA1 levels, and measurement of anti-IgA1 immunoglobulins. While targeted treatment for IgAN remains elusive, there is mounting evidence for therapeutic interventions that alter the disease course. The appropriate validation and integration of these discoveries into clinical care represent a major challenge, but one that holds tremendous promise for refining prognostication, guiding therapy, and improving the lives of patients with IgAN.
Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York.
Pietro A
PA
Canetta
Krzysztof
K
Kiryluk
Gerald B
GB
Appel
D001323:Autoantibodies / Q000097:blood; D001706:Biopsy; D005819:Genetic Markers; D005922:Glomerulonephritis, IGA / Q000175:diagnosis* / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007678:Kidney Glomerulus / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D014068:Tonsillectomy; D016896:Treatment Outcome
D001323:Autoantibodies; D005819:Genetic Markers; D007070:Immunoglobulin A; D007166:Immunosuppressive Agents